Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC)

Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC) - Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180304

Enrollment

Registered

2019-03-15

Start date

2016-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma asthma

Interventions

Divide into Fluticasone control group and SFC control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Physician diagnosed asthma( More than 3 wheeze episode) More than 2 asthma attacks for 8 weeks LTRA is taken for more than 1month as a controller

Exclusion criteria

Exclusion criteria: SFC or Fluticasone is used as a controller Patients has respiratory diseases except asthma

Design outcomes

Primary

Measure	Time frame
In patients with a common cold, asthma control was significantly more effective for those treated with SFC compared to treatment with Fluticasone	—

Secondary

Measure	Time frame
In 12th week SFC group will show higher Best ACT P score and QOL score than fluticasone group. SFC group will less frequently to use b stimulator and less frequently to visit ER department.	—

Contacts

Public ContactHironobu Hukuda

Dokkyo Medical University Hospital

h-hukuda@dokkyomed.ac.jp+81-282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026